{"filings":[{"id":776396,"accession_number":"0001698530-26-000060","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-06-01T19:30:08+00:00","items":["7.01","9.01"],"status":"ready","headline":"Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delinquency notice on May 28, 2026 for late Q1 2026 10-Q filing.","Delayed due to changes in financial reporting personnel and related procedures.","Filed the delinquent 10-Q on May 29, 2026, one day after the notice.","Believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94789,"accession_number":"0001698530-26-000036","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exicure appoints Yoontae Han as director, Dongho Lee as Audit Chair, Young Seung Ko as COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yoontae Han appointed director and Audit Committee member effective April 8, 2026; $20,000 annual retainer.","Dongho Lee appointed Chair of the Audit Committee.","Young Seung Ko appointed COO effective April 9, 2026; former CEO of AGEDB Technology.","Company to pay Innocircle Advisors additional $10,000 monthly fee for COO services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94788,"accession_number":"0001698530-26-000034","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure derivative settlement preliminarily approved; includes governance reforms and $675k fee","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court preliminarily approved settlement on March 19, 2026; final hearing set for June 2, 2026.","Settlement requires Exicure to adopt and maintain corporate governance reforms for at least four years.","Defendants' insurers to pay $675,000 in attorneys' fees and expenses to plaintiffs' counsel, subject to court approval.","Plaintiffs may receive service awards of up to $2,000 each from the fee amount.","Settlement resolves derivative actions in Illinois and Delaware plus a stockholder demand with prejudice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107407,"accession_number":"0001698530-26-000031","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exicure director Sangjin Yeo resigns from Board and Audit Committee effective March 27, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sangjin Yeo submitted resignation on March 25, 2026, effective March 27, 2026.","Resignation covers both the Board of Directors and the Audit Committee.","Company states the resignation did not result from any disagreement over operations, policies, or practices.","No replacement appointed or announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107406,"accession_number":"0001698530-26-000026","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure FY2025 net loss $4.9M; cash $3.7M; warns cash insufficient for 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $3.7M as of Dec 31 2025, down from $12.5M a year ago.","Net loss $4.9M for FY2025 vs $9.7M in FY2024; decrease due to $6.0M lease termination gain.","R&D expenses rose to $3.3M from $0 reflecting GPCR USA acquisition; G&A $6.8M vs $5.4M.","Company states existing cash may not be sufficient to fund operations for next 12 months.","Management engaged in cost reductions but limited; substantial additional financing required short term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107405,"accession_number":"0001698530-26-000013","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exicure appoints Jung Soo Kim as CEO and Gyuyeob Lee as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Andy Yoo and CFO Seung Ik Baik resigned effective Feb 9, 2026.","Jung Soo Kim appointed CEO and President effective Feb 11, 2026.","Gyuyeob Lee appointed Interim CFO and Secretary effective Feb 11, 2026.","Kim has over 20 years in corporate strategy; also CEO of Sandcraft Inc. and AGEDB Technology.","Lee has experience in governance restructuring; branch manager of AGEDB Technology Vancouver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107404,"accession_number":"0001698530-26-000009","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exicure CEO Andy Yoo, CFO Seung Ik Baik resign; three new directors appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andy Yoo resigned as CEO/President and Seung Ik Baik as CFO/Secretary, effective Feb 9, 2026; no successors named.","Three directors (Yoo, Baik, Aejin Hwang) resigned; Board appointed Jung Kyu Ham, Jung Soo Kim, Gyeung Seog Cheon.","Outgoing CFO Baik received $150k separation payment; outgoing director Hwang and two remaining directors each got one-time $20k.","New directors receive $20k annual retainer; Cheon appointed to audit committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107403,"accession_number":"0001698530-26-000007","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.","Milestone payment of $1,000,000 due to GPCR Therapeutics Inc. within 30 days.","Achievement triggers improved future sublicensing income-sharing ratio for Exicure.","Milestone reflects progress in development of small-molecule CXCR4 inhibitor Burixafor (GPC-100)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123755,"accession_number":"0001698530-25-000105","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure redeems 4.5B KRW (~$3.125M) in convertible bonds from subsidiary KC Creation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redeemed 4.5B KRW ($3.125M) of 2.90% Convertible Bonds due 2028 issued by wholly-owned subsidiary KC Creation.","Bonds originally issued April 30, 2025; part of internal capital structure with no third-party holders.","Redemption funded via internal cash transfers; aims to simplify intercompany financing and secure liquidity for biotech operations.","Transaction eliminated in consolidation; no material impact on consolidated financial statements expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123754,"accession_number":"0001698530-25-000102","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Exicure stockholders elect directors, ratify auditor, and approve executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sangjin Yeo and Aejin Hwang elected Class II directors with 3,481,839 votes each; no withhold votes.","Ratification of CBIZ CPAs P.C. as independent auditor for FY2025 approved: 3,750,205 for, 12,485 against.","Non-binding advisory vote on named executive officer compensation passed: 3,478,408 for, 3,931 against.","Broker non-votes totaled 293,024 on director election and advisory compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123753,"accession_number":"0001698530-25-000099","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure Q3 net loss widens to $2.4M; cash burn and going concern warning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents fell to $4.4M at Sep 30, 2025 from $12.5M at Dec 31, 2024.","Net loss of $2.4M (Q3 2025) vs $1.1M (Q3 2024), driven by GPCR acquisition costs.","R&D expense rose to $0.9M (from $0) due to acquired GPCR USA research activities.","Management says existing cash insufficient; substantial additional financing needed short-term."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140440,"accession_number":"0001698530-25-000081","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Exicure appoints two new directors; four directors resign effective Sept 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sangjn Yeo and Aejin Hwang to the Board as Class II directors; Yeo appointed Chairman of audit committee.","Four directors resigned: Ho Jung John, Chang Keun Choi, Sangwook Song, Minwoo Kang, effective immediately.","Resignations not due to any disagreement on operations, policies, or practices.","Board now has four vacancies after these changes.","New directors will receive $20,000 annual retainer and standard indemnification agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140439,"accession_number":"0001698530-25-000076","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure reports Q2 net loss of $2.6M; warns going concern, needs financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents fell to $7.9M at June 30, 2025, from $12.5M at Dec 31, 2024.","Net loss widened to $2.6M for Q2 2025 vs $0.6M in Q2 2024, driven by GPCR USA acquisition costs.","R&D expense rose to $0.9M from $0 in prior-year quarter; G&A expense increased to $1.5M.","Management states existing cash insufficient to fund operations; substantial additional financing needed short-term."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140438,"accession_number":"0001698530-25-000071","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure regains compliance with Nasdaq periodic filing requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["As of July 1, 2025, Exicure regained compliance with Nasdaq Listing Rule 5250(c)(1).","Compliance confirmed by filing Form 10-Q for fiscal quarter ended March 31, 2025.","Nasdaq sent formal notice confirming compliance and resolving the matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158115,"accession_number":"0001698530-25-000054","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure reports Q1 net income of $3.0M on lease gain; warns cash insufficient for operations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $10.4M (Dec 2024: $12.5M); net income $3.0M vs loss $0.8M YoY.","Net income driven by $6M gain from early Chicago lease termination; reversed lease liability.","R&D expense $0.8M (prior year $0) and G&A $2.2M ($1.3M) due to GPCR USA acquisition costs.","Going concern: existing cash not sufficient to fund operations; additional financing needed short-term.","Company engaged in cost cuts but limited ability to extend runway further."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158114,"accession_number":"0001698530-25-000047","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Exicure raises CEO salary to $480K, CFO to $300K; CEO gets 24-month severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Andy Yoo salary increased to $480,000; CFO Seung Ik Baik salary increased to $300,000.","CEO severance set at 24 months' base salary if terminated without cause.","CFO severance set at 12 months' base salary if terminated without cause.","Changes effective as of April 1, 2025; no other compensation terms altered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158113,"accession_number":"0001698530-25-000044","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Exicure receives Nasdaq delinquency notice for late Q1 2025 Form 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delinquency notice on May 21, 2025 for failure to timely file Form 10-Q for quarter ended March 31, 2025.","Company has 60 calendar days to submit a compliance plan; Nasdaq may grant extension until November 17, 2025.","Exicure is working diligently to complete and file the Form 10-Q as soon as practicable.","Non-compliance with Nasdaq Listing Rule 5250(c)(1) requiring timely periodic financial reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158112,"accession_number":"0001698530-25-000035","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Exicure invests ~$3.125M in convertible bonds of wholly-owned subsidiary KC Creation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subscription amount of KRW 4.5B (≈$3.125M) for non-guaranteed private placement convertible bonds.","Bonds mature April 30, 2028; yield to maturity 2.9% compounded quarterly.","Proceeds to be used for acquisition of stocks of other corporations.","Put option exercisable after one year and quarterly thereafter; conversion price 901 KRW ($0.63) per share.","Conversion period from April 30, 2026 to March 31, 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158111,"accession_number":"0001698530-25-000030","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Exicure replaces auditor Marcum with CBIZ CPAs after resignation; prior reports had going concern qualification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on April 10, 2025; CBIZ CPAs engaged immediately for 2025.","No disagreements between Exicure and Marcum on accounting principles or audit scope during 2023-2024.","Audit reports for 2023 and 2024 included a going concern explanatory paragraph.","Material weakness in internal control over financial reporting (disclosed June 2023) remains unremediated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176488,"accession_number":"0001698530-25-000017","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure reports FY2024 net loss of $9.7M, cash $12.5M, going concern warning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $12.5M as of Dec 31, 2024, up from $0.8M year-end 2023; management warns liquidity may not last 12 months.","Net loss of $9.7M for FY2024, compared to net loss of $16.9M in FY2023; decrease driven by lower G&A and asset sale income.","R&D expenses $0 for FY2024 (from $1.4M) reflecting cessation of all R&D activities; G&A expenses $5.4M (from $11.7M).","Company continues exploring strategic alternatives, including transactions with potential partners; substantial doubt about going concern.","Sold clinical product samples and certain assets in 2024 to a private biopharma; no further operational details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176487,"accession_number":"0001628280-25-010535","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Exicure board members Jiyoung Hwang and Paul Kang resign; Kang to provide consulting for 12 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jiyoung Hwang resigned from the Board on Feb 28, 2025 for personal reasons; no disagreement.","Paul Kang resigned from the Board effective March 3, 2025; will provide transitional consulting services for 12 months.","Consulting agreement with Kang executed on Feb 27, 2025; Kang previously served as co-CEO after Andy Yoo was appointed CEO on Dec 17, 2024.","Both resignations were not due to any disagreement with Company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176486,"accession_number":"0001698530-25-000009","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Exicure raises ~$2M in stock sale to two investors; records $6M lease-termination gain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$2M via sale of 290,908 shares at $5.50 each to Shin Chang Partners and RMS0718 Co., Ltd.","Registration Rights Agreement requires filing within 60 days of closing; 0.5% monthly liquidated damages up to 4% cap.","Executed Lease Termination Agreement effective Jan 31, 2025; vacated Chicago office with no additional fees.","Recognized $6M gain from early lease termination in Q1 2025; lease originally expired June 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176483,"accession_number":"0001698530-25-000006","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K/A","filed_at":"2025-01-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.","Entered License and Collaboration Agreement to develop and commercialize GPCR's technologies and patents.","Must make milestone payments tied to clinical trial, regulatory, and sales milestones; royalty of at least 10% of net sales.","Corrected press release filed as an amendment to the January 22, 2025 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176485,"accession_number":"0001698530-25-000004","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Exicure buys GPCR USA for ~$1.62M; milestone & royalty deal with GPCR Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Acquired all outstanding shares of GPCR Therapeutics USA from GPCR Therapeutics for ~$0.27/share (total ~$1.62M).","Entered License and Collaboration Agreement to develop and commercialize GPCR's IP; includes milestone payments and 10% royalty on net sales.","Example milestone: $30M payment when first annual net sales exceed $400M.","Deal closed concurrently with execution on January 19, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176484,"accession_number":"0001698530-25-000002","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exicure receives $8.7M from HiTron, appoints audit committee members","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $8.7M on Dec 24, 2024 from closing of Common Stock Purchase Agreement with HiTron Systems Inc.","Chang Keun Choi and Minwoo Kang appointed to Board effective Dec 19, 2024; both added to Audit Committee effective Jan 1, 2025.","Minwoo Kang named Chair of the Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193339,"accession_number":"0001698530-24-000151","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure regains Nasdaq compliance but faces one-year monitoring period with risk of immediate delisting if violated","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 20, 2024, Nasdaq confirmed Exicure meets all requirements for continued listing as of Dec 17, 2024.","Company had previously been notified of non-compliance with $2.5M stockholders' equity requirement; its deficit was $2.2M as of Mar 31, 2024.","Exicure is now subject to a one-year Mandatory Panel Monitor; any future non-compliance could result in immediate delisting without a cure period.","The company achieved compliance through transactions disclosed in a Dec 17, 2024 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193332,"accession_number":"0001698530-24-000150","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K/A","filed_at":"2024-12-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Exicure shareholders approve $8.7M HiTron investment; CEO and board changes; Nasdaq plan presented","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved $8.7M second investment from HiTron; total HiTron investment $10M at $3/share.","Upon close, HiTron becomes Exicure's largest shareholder with >50% ownership.","Board expanded to 9 directors; 4 new directors appointed; Andy Yoo named CEO effective Dec 19, 2024.","Company plans additional ~$2.4M raise targeting total ~$15M; in discussions with a US therapeutics company.","Presented Nasdaq compliance plan on Dec 17, 2024 for equity requirement; awaiting Panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193338,"accession_number":"0001698530-24-000144","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Exicure shareholders approve $8.7M HiTron investment; change of control, new CEO and board","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Shareholders approved 2.9M shares to HiTron at $3/share for $8.7M second investment, totaling $10M; HiTron holds >50%.","Board expanded to nine; four new directors appointed (John, Choi, Song, Kang); multiple prior directors resigned.","Andy Yoo appointed CEO/President ($300K base), Seung Ik Baik as CFO ($130K), Jiyoung Hwang as CSO ($150K).","Additional $2M raised from SangSang Investment at $4.61/share, closed December 12, 2024.","Company presented Nasdaq compliance plan to regain equity requirement; awaiting panel decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193337,"accession_number":"0001698530-24-000139","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure raises $12M via stock sales to regain Nasdaq equity compliance; pro forma equity ~$4.3M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Sold 433K shares to HiTron Systems at $3/share for $1.3M net proceeds on Nov 21, 2024.","Agreed to sell 2.9M additional shares to HiTron at $3/share for $8.7M, approved by shareholders on Dec 17, 2024.","Sold 433,332 shares to SangSang at $4.61/share for ~$2M net proceeds on Dec 12, 2024.","Pro forma stockholders' equity rose from $1.18M (Oct 31) to $4.29M, exceeding the $2.5M Nasdaq minimum.","Company awaits Nasdaq confirmation of compliance with the Equity Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193336,"accession_number":"0001698530-24-000136","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Exicure to issue 433,332 shares at $4.61 for $2M gross proceeds to SangSangIn","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common Stock Purchase Agreement with SangSangIn Investment & Securities Co., Ltd.","433,332 shares at $4.61 per share; expected gross proceeds of approx. $2 million.","Closing expected within ten days after December 9, 2024; registration rights granted.","Private placement under Section 4(a)(2); accredited investor representation.","Proceeds for general corporate purposes and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193335,"accession_number":"0001698530-24-000123","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Exicure appoints new board members and CRO; receives $1.3M from HiTron deal closing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andy Yoo appointed as Class I director and Chief Restructuring Officer; Seung Ik Baik as Class III director effective Nov 21, 2024.","Yoo receives $200,000 annual base salary as officer; both directors get $20,000 annual retainer and standard indemnification.","Hojoon Lee and Eui Yull Hwang resigned from board for personal reasons, effective immediately; no disagreements cited.","Company received $1.3 million upon closing of Common Stock Purchase Agreement with HiTron Systems Inc. on Nov 21, 2024.","Yoo is CEO of HiTron; appointments made pursuant to HiTron rights under the Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193334,"accession_number":"0001698530-24-000119","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Exicure gets Nasdaq extension to Dec 17; delisting risk persists","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension to December 17, 2024, for listing compliance.","Company must evidence compliance with all continued listing criteria; no further extensions allowed.","Working to satisfy requirements via financing transaction with HiTron Systems Inc.","No assurance it can regain or maintain compliance; delisting remains possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193333,"accession_number":"0001698530-24-000116","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"Exicure announces $10M equity financing from HiTron, Q3 net loss $1.1M, cash $0.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial sale of 433,333 shares at $3.00/share to HiTron for $1.3M; closing expected within 10 days.","Subsequent sale of 2.9M shares at $3.00/share for $8.7M, conditioned on stockholder approval.","Upon initial close, HiTron gets right to nominate two board members; additional seats on subsequent close.","Cash and cash equivalents $0.3M as of Sept 30, 2024; company says insufficient to fund operations.","Q3 2024 net loss $1.1M vs $5.3M in Q3 2023; includes $1.5M asset sale revenue and $2M bond write-down in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209689,"accession_number":"0001698530-24-000110","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["1.01","2.01","5.02","9.01"],"status":"ready","headline":"Exicure sells core SNA technology to Flashpoint for $1.5M; appoints new director","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold spherical nucleic acid technology, R&D programs, and clinical assets to Flashpoint Therapeutics for $1.5 million gross proceeds.","Will receive royalties on future licensing or sublicensing of the assets by Flashpoint.","Board increased to seven; Eui Yull Hwang appointed as independent Class II director.","No material relationship exists between Exicure and Flashpoint aside from the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209688,"accession_number":"0001698530-24-000106","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nasdaq Panel grants Exicure listing extension until Nov 14, 2024; debt-to-equity swap completed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Extension granted on Sept 17, 2024; must evidence compliance with all continued listing criteria by Nov 14, 2024.","Previously regained compliance with Nasdaq minimum bid price requirement.","Exchanged ~$1M of indebtedness for equity at $3.00 per share.","Company working to satisfy Panel terms; risk of delisting remains if not compliant by deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209687,"accession_number":"0001698530-24-000101","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01","3.02","8.01"],"status":"ready","headline":"Exicure converts $1M debt to equity at $3/share; regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $700K promissory note from DGP Co., Ltd. into 237,233 shares at $3.00/share.","Converted $300K promissory note from individual holder into 101,991 shares at $3.00/share.","DGP is largest shareholder (~35% ownership pre-conversion); shares issued unregistered under Section 4(a)(2).","Regained Nasdaq minimum bid price compliance after closing bid ≥ $1.00 for 10 consecutive sessions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209686,"accession_number":"0001698530-24-000098","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Exicure announces 1-for-5 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-5 ratio effective 5:00 pm ET Aug 27, 2024; trading on split-adjusted basis from Aug 28.","Outstanding shares reduced from approx. 8.65M to approx. 1.73M; par value unchanged; no fractional shares issued.","Stockholders approved reverse split range at special meeting Aug 20; board set 1-for-5 ratio same day.","Split intended to help regain compliance with Nasdaq minimum bid price listing rule; stock continues under ticker XCUR.","New CUSIP number 30205M309; no change in authorized shares or percentage ownership (except for fractional share rounding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209685,"accession_number":"0001698530-24-000093","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure special meeting adjourned again to Aug 20; only 49.7% shares voted","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting adjourned from Aug 19 to Aug 20, 2024 at 9:00 AM CT due to lack of quorum.","Quorum requires majority of outstanding shares; 49.7% of shares had submitted proxies as of adjournment.","Record date remains July 26, 2024; previously submitted proxies remain valid unless revoked.","Stockholders who have not voted are encouraged to vote online at www.proxyvote.com or by phone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209684,"accession_number":"0001698530-24-000091","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Exicure special meeting adjourned; quorum not reached at 49.4% votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on Aug 15 adjourned due to lack of quorum; only 49.4% of outstanding shares voted.","Meeting reconvened on Aug 19, 2024 at 9:00 a.m. CT; record date remains July 26, 2024.","Stockholders who already voted need not take action; others may vote via internet or phone.","Proposal described in proxy statement filed July 30, 2024 is the subject of the vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209683,"accession_number":"0001698530-24-000088","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure Q2 2024 net loss $0.6M; cash only $0.5M, warns of insufficient funding and going concern","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $0.5M at June 30, 2024, down from $0.8M at Dec 31, 2023.","Net loss improved to $0.6M from $5.8M in Q2 2023, driven by cost cutting and $0.6M other income from product sample sales.","Management states cash insufficient to fund operations; substantial additional financing needed in the very near term.","Company halted all R&D in Sept 2022 and continues exploring strategic alternatives to maximize stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209682,"accession_number":"0001698530-24-000084","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Exicure gets Nasdaq continued listing with Sept. 16 compliance deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to continue Exicure's listing subject to evidencing compliance by September 16, 2024.","Formal notice received July 31, 2024; press released August 1, 2024.","Company must satisfy all applicable continued listing criteria on Nasdaq Capital Market.","Exicure is working diligently to meet the Panel's terms and ensure continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209681,"accession_number":"0001698530-24-000074","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Exicure stockholders elect four directors, ratify Marcum as auditor, approve say-on-pay at 2024 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors Paul Kang (4,389,180 for) and Hyuk Joon Ko (4,381,669 for); Class I directors Jiyoung Hwang (4,290,978 for) and Dongho Lee (4,381,699 for).","Ratified Marcum LLP as independent auditor for FY 2024: 4,504,318 for, 18,965 against, 4,176 abstain.","Advisory vote on named executive officer compensation approved: 4,356,290 for, 153,415 against, 17,754 abstain.","Stockholders recommended 'one year' frequency for future advisory votes: 4,499,406 for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227818,"accession_number":"0001698530-24-000071","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Exicure receives Nasdaq delisting notice for minimum equity failure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delinquency notice on June 20, 2024 for non-compliance with minimum $2.5M stockholders' equity requirement.","Company to address this deficiency in its pending appeal before Nasdaq Hearings Panel on July 9, 2024.","Failure to regain compliance could result in delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227817,"accession_number":"0001698530-24-000067","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.","Received $0.7M loan from DGP Co., Ltd. after May 31; 6% interest, 10-month maturity.","Revenue of $0.5M from patent license for cavrotolimod (hepatitis) with private biopharma.","Net loss improved to $0.8M from $4.4M YoY due to cost cuts and license revenue.","Company states existing cash insufficient; substantial near-term financing needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227816,"accession_number":"0001698530-24-000049","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["2.02","2.03","9.01"],"status":"ready","headline":"Exicure reports FY 2023 net loss of $16.9M; cash drops to $0.2M; receives $700K loan from stockholder","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents fell to $0.8M at Dec 2023 and further to ~$0.2M by May 31, 2024.","Received $700K loan from DGP Co., Ltd. (significant stockholder) at 6% interest, due in ten months.","Net loss for FY 2023 was $16.9M compared to $2.6M in FY 2022.","R&D expenses dropped to $1.4M from $19.8M due to complete halt of R&D activities.","Management states cash insufficient to fund operations; substantial additional financing needed in very near term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227815,"accession_number":"0001698530-24-000034","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Exicure faces Nasdaq delisting for failure to file FY2023 10-K, Q1 2024 10-Q, and missing annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Exicure on May 21 of delisting; trading suspension effective May 30 unless appeal by May 28.","Delinquencies: FY2023 Form 10-K (missed extended deadline May 20), Q1 2024 Form 10-Q, and 2023 annual meeting not held.","Company intends to appeal by May 28; suspension stayed 15 days automatically; will seek longer stay.","No assurance of regaining compliance; if delisted, Nasdaq will file Form 25-NSE to remove stock from exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227814,"accession_number":"0001698530-24-000029","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Exicure cash drops to $0.2M; warns going concern, needs funding imminently","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents fell from $8.6M (Dec 31, 2022) to $0.9M (Sep 30, 2023); further to ~$0.2M by Apr 30, 2024.","Net loss Q3 2023 was $5.3M, roughly flat vs $5.2M a year ago; R&D expense fell to $0 after halting all programs.","Company states cash insufficient to fund operations; substantial additional financing needed in very near term.","No revenue or pipeline activity; exploring strategic alternatives to maximize stockholder value.","Going-concern warning: management believes existing cash cannot sustain operations without immediate funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227813,"accession_number":"0001698530-24-000017","cik":1698530,"company_name":"EXICURE, INC.","ticker":"XCUR","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Exicure receives Nasdaq delinquency notice for late 10-K; must comply by May 20, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 17, 2024, Nasdaq notified Exicure of non-compliance for failing to file its 2023 Form 10-K (Rule 5250(c)(1)).","Exicure was already delinquent on its Q3 2023 Form 10-Q; prior exception expires May 20, 2024.","Any additional exception for both delinquent filings is limited to May 20, 2024.","Company is working diligently to complete and file the Form 10-K to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18420000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}